Compare Kinder Morgan Inc (KMI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Organon & Co. Common Stock — how do they compare? Kinder Morgan Inc trades at $33.37 (market cap $74.44B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Kinder Morgan Inc is far larger — about 20.6× Organon & Co. Common Stock's market cap, and Kinder Morgan Inc pays the higher dividend (3.53%). Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 151 Days and Organon & Co. Common Stock for 0 Days on average.
| KMI | OGN | |
|---|---|---|
Market Cap | $74.44B | $3.62B |
Volume | 10,771,998 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $34.31 | $13.81 |
52-Week Low | $25.84 | $5.70 |
Typical Hold Time | 151 Days | 0 Days |
Enterprise Value | $106.49B | $11.04B |
Dividend Yield | 3.53% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $33.35, up 0.82% with a bullish technical outlook. The company delivered three consecutive earnings beats in 2026, with Q3 results pending. Revenue grew to $16.94B in 2025, while net income reached $3.06B. Analyst consensus is mixed with a $37.20 price target, representing 11.5% upside. Recent news highlights the company's $6B-$7B growth pipeline and resilience amid energy market volatility.
KMI offers income investors a compelling opportunity with strong cash flows and a visible growth backlog, though elevated debt levels and energy market sensitivity present risks. The stock's current valuation appears reasonable relative to peers, with technical indicators supporting near-term bullish momentum.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
